Douglas S. Ingram

Douglas S. Ingram

Chief Executive OfficeratSarepta Therapeutics· In proxies 2021–2025

Pay in FY2025+296% from the year before · Sarepta Therapeutics stock -82.3% the same year

Douglas S. Ingram was paid $7.8M in FY2025 (Dec), up 296%. Sarepta Therapeutics stock fell 82.3% that year.

Pay$100 in the stock at the end of FY20 → $13
Pay is from the Summary Compensation Table of each Sarepta Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Sarepta TherapeuticsPublic company · 5 yr
    • Chief Executive Officer2021 – Present · 5 yrStock in role -89%
  2. Relay TherapeuticsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  3. Relay TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years
  4. Arrowhead Pharmaceuticals, Inc.Public company · 1 yr
    • Director2025 – 2026 · 1 yrNo stock prices for these years
  5. Pacific Mutual Holding CompanyPublic company · 3 yr
    • Director2015 – 2018 · 3 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards2

  • Sarepta TherapeuticsDirector · 8 yr on the boardNot independent—Paid as an executive
  • Relay TherapeuticsDirector · 5 yr on the boardIndependentCompensation (Chair)—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?